Powered by

Innovent Reports Interim Results for Fiscal Year 2019

Aug 28, 2019 - PR Newswire
Financial Results

PR Newswire

 Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced its interim financial results for the six months ended June 30, 2019.

HIGHLIGHTS AND OTHER RECENT UPDATES

Total revenue was RMB345.5 million, including RMB331.6 million attributable to sales of Tyvyt® (sintilimab injection), which is Innovent's first commercial drug product, received marketing approval...